by draivika_incrowd | Nov 18, 2021 | Report
With COVID-19 case numbers down and vaccines available to more of the population, InCrowd wanted to understand how these changes will impact telehealth. We asked 100 US opinions for their opinions on the future of telehealth and their hopes for payer coverage....
by draivika_incrowd | Nov 3, 2021 | Report
With pediatric COVID-19 vaccine supplies rolling out, InCrowd sourced data from 120 pediatricians to gauge how pediatricians feel about their age-appropriate patients receiving the vaccine, understand how many patients are expected to get vaccinated, and learn how...
by draivika_incrowd | Oct 26, 2021 | Report
Subsequent to a report of a chromosomal abnormality in CAR T-cells in a patient treated in an allogeneic CAR T-cell therapy clinical trial, the FDA has placed a hold on allogeneic CAR T-cell therapy clinical trials being conducted by that company. InCrowd wanted to...
by draivika_incrowd | Oct 13, 2021 | Report
As a key FDA committee meets this week, 86% of doctors agree on Pfizer-BioNTech COVID-19 booster shot importance for key groups, but estimate they miss 46% of their patient base. Our COVID-19 vaccine booster shot survey reflects data from n=101 US physicians...
by draivika_incrowd | May 21, 2021 | Report
The field of oncology biomarker testing is growing rapidly. With so many new cancer treatments available requiring specific biomarkers for prescription, oncologists have plenty of new information to follow and many decisions to make when treating individual tumors.*...
by draivika_incrowd | May 3, 2021 | Report
Given the ongoing roll-out of the COVID-19 vaccine across the US, InCrowd conducted its fourth wave of research on perceptions and observations of infectious disease experts on the COVID-19 vaccine to gauge progress and further predictions. This report compares recent...
